Advertisement

PharmacoEconomics & Outcomes News

, Volume 832, Issue 1, pp 25–25 | Cite as

Pembrolizumab/axitinib too costly in advanced renal cell carcinoma

Clinical study

Reference

  1. Chen J, et al. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. Clinical Drug Investigation : 27 Jun 2019. Available from: URL: http://doi.org/10.1007/s40261-019-00820-6

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations